22 results about "Peptide hormone" patented technology

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards5 to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The present invention provides novel compounds that are peptide hormone analogs and are useful for treating disorders such as diabetes and obesity.The compounds of the general sequence listed herein have tailored profiles of potency at the GIP receptor.Regarding in vivo properties, administration of exemplary peptides of the present invention has been shown to result in improved weight loss in animal models.Preferred compounds achieve this without significantly reducing food intake.

The present invention provides novel compounds which are peptide hormone analogs and are useful in the treatment of conditions such as diabetes and obesity. Compounds of the general sequence listed in the specification have a tailored profile with respect to potency characteristics for GIP receptors. Administration of example peptides of the invention has been demonstrated in animal models about in vivo characteristics to result in increased weight loss. Preferred compounds achieve this without significantly reducing food intake.

The invention relates to the technical field of biological medicines, in particular to application of parthenolide and / or parthenolide derivatives in preparation of medicines for preventing and / or treating diabetes mellitus and in preparation of products for body weight intervention and / or blood sugar maintenance. The bitter compound parthenolide can be obtained from a natural product and is safe in component, the binding energy of parthenolide and GLP1R on the atomic level is-6.3 kcal / mol, parthenolide can serve as a GLP-1 receptor agonist and can promote GLP-1 secretion, the onset concentration of parthenolide is low (15-30 [mu] M), and it is indicated that parthenolide serves as a receptor to excite the secretion of intestinal peptide hormone, and the titer intensity of parthenolide is high. Therefore, parthenolide and / or parthenolide derivatives are / is a secretagogue which efficiently secretes GLP-1 and is low in side effect, are / is a promising direction for improving the endogenous GLP-1 level, provide a good scientific basis for developing products for effectively intervening body weight and maintaining the blood sugar health level in the future, and have great potential market value.

The present invention relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, in a human female subject, by administering a non-incretin peptide hormone.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The disclosure provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The invention discloses a marker for microbiological positive diagnosis of tuberculous pleurisy pleural effusion as well as a screening method and application of the marker, and relates to the technical field of biological detection. The marker comprises at least one of lactic dehydrogenase, an immunoglobulin lambda variant 2-18, a peptide hormone retinol binding protein 4, an immunoglobulin lambda variant 3-21 and a microtubulin alpha-1C chain. The lactic dehydrogenase combined immunoglobulin lambda variants 2-18 in the marker can significantly improve the microbiological positive diagnostic rate of tuberculous pleurisy pleural effusion.

The disclosure provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

In various aspects and embodiments, the present disclosure provides DNA constructs and compositions thereof for expressing peptide hormones in muscle tissue, and particularly peptide hormones such as glucagon-like peptide-1 (GLP-1) receptor agonists, glucose- dependent insulinotropic polypeptide (GIP) receptor agonists, and / or glucagon (GCG) receptor agonists, as well as dual and triple agonists. The disclosure further provides uses of these constructs in methods for treating disease, including metabolic diseases or diseases involving hyperglycemia, insulin resistance, obesity, and / or metabolic syndrome.

The present invention provides novel compounds that are peptide hormone analogs and can be used to treat conditions such as diabetes and obesity. With respect to efficacy properties at glucagon and GLP-1 receptors, compounds of the general sequence listed in the specification have a customized profile. With respect to in vivo properties, it has been demonstrated in animal models that administration of the exemplary peptides of the present invention results in increased weight loss. Preferred compounds achieve this without significantly reducing food intake.

The invention relates to an unbalanced peptide hormone prediction method based on a protein language model. The method solves the problem that in the prior art, the identification performance of a peptide hormone prediction method is reduced under the condition of class imbalance. The method comprises the following steps: S1, collecting and preprocessing a data set; s2, embedding and coding sequence features; s3, constructing a model; s4, performing model performance optimization; s5, performing model performance evaluation; s6, performing practical application and expansion; and S7, realizing and deploying the system. The method has the advantages that the potential structure and function association of the peptide sequence can be automatically learned under the condition that artificial feature design is not needed. Meanwhile, aiming at the problem of class imbalance that the number of peptide hormone samples is far less than that of non-hormone peptides, the recognition capability of the model on minority class samples is enhanced, and the balance and robustness of overall prediction are remarkably improved.

The present invention relates to therapeutic and non-therapeutic methods of using peptide hormone analogs. In particular, the present invention relates to the use of amylin analogs with improved properties, in particular amylin analogs that do not delay gastric emptying.

The disclosure provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the glucagon and GLP-1 receptors. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

Novel indication for adropin to prevent or treat vasospasm, brain injury, or cerebral edema.

Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.

A compound having an amino acid sequence of Formula (I): Xaa1- AIB2- Xaa3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Xaa10-Ser11- Lys12- Gln13- Leu14- Glu15- Glu16-Xaa17-Xaa18-Val19-Xaa20-Xaa21-Phe22- Ile23- Glu24

The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

The invention discloses application of PSK to improvement of asexual propagation efficiency of lily scales, belongs to the technical field of plant asexual propagation, and particularly aims to solve the problems that existing lily scale cutting propagation is low in efficiency, slow in budding and rooting and the like. The PSK with the effective concentration (preferably 10 nM <-1 > mu M) is prepared into a treatment solution; during cuttage, the water is applied as first-time irrigation liquid, and the physiological response of the scales can be systematically regulated and controlled. Experiments show that the application can significantly improve the budding rate of longya lilium scales, promote the expansion of new bulblets, and synchronously improve the rooting rate. The invention provides a novel efficient asexual propagation method for lily, which is simple and convenient to operate, remarkable in effect and safe, and is suitable for large-scale production of lily seedlings.